Amount of suitable people: CDEC talked over the uncertainty in the number of patients with moderately extreme to extreme hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who're categorised as acquiring gentle or average condition could possibly have a critical b